Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Irinotecan pathway genotype analysis to predict pharmacokinetics.

Ron H J Mathijssen1, Sharon Marsh, Mats O Karlsson

  • 1Department of Medical Oncology, Erasmus MC-Daniel den Hoed Cancer Center, 3075 EA Rotterdam, the Netherlands.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|September 10, 2003
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Strain-dependent neuronal disposition and toxicity of paclitaxel in mice.

ASPET discovery·2026
Same author

Ribociclib is not a substrate or inhibitor of Oatp1b-mediated uptake in vivo.

Cancer chemotherapy and pharmacology·2026
Same author

Mechanisms Underlying Cedazuridine-Mediated Enhancement of Oral Decitabine Bioavailability.

Cancer research communications·2026
Same author

Role of solute carrier transporters in the biodistribution and toxicity of chemotherapeutic drugs.

Pharmacological reviews·2026
Same author

Pacific Blue Derivatives of Paclitaxel as Fluorescent Probes of OATP1B-Type Transporters.

Clinical and translational science·2026
Same author

OATP2B1 Deficiency Ameliorates Irinotecan-Induced Gastrointestinal Toxicity.

Clinical and translational science·2025

Genetic variants in ABCB1 influence irinotecan exposure, suggesting ABCB1 1236C>T genotyping can aid in optimizing irinotecan chemotherapy doses for cancer patients.

Area of Science:

  • Pharmacogenomics
  • Cancer Chemotherapy
  • Drug Metabolism

Background:

  • Irinotecan is a widely used chemotherapy drug.
  • Its efficacy and toxicity are influenced by individual genetic makeup.
  • Understanding genetic variations in drug transporters and metabolizing enzymes is crucial for personalized medicine.

Purpose of the Study:

  • To investigate the association between genetic variants of ATP-binding cassette transporters and key metabolic enzymes with irinotecan disposition.
  • To identify genetic markers that could predict irinotecan pharmacokinetics and potentially guide treatment decisions.

Main Methods:

  • Pharmacokinetic analysis of irinotecan and its metabolite SN-38 in 65 cancer patients.
  • Genotyping for variants in genes including ABCB1, ABCC1, ABCC2, ABCG2, CES1, CES2, CYP3A4, CYP3A5, UGT1A1, and XRCC1.

Related Experiment Videos

  • Statistical analysis to correlate genetic variants with pharmacokinetic parameters.

    • Main Results:

    • Eighteen genetic variants were identified in nine genes relevant to irinotecan.
    • The ABCB1 1236C>T polymorphism (homozygous T allele) was significantly associated with increased exposure to irinotecan and SN-38.
    • No significant associations were found for other variants, possibly due to low allele frequencies.

    Conclusions:

    • Genotyping for the ABCB1 1236C>T variant may assist in optimizing irinotecan dosage for cancer patients.
    • Further research in larger, diverse populations is needed to validate these findings and explore rare variants.